Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis

Table 1 General information of included studies

Study	Language	Number		Number of gender (Male/Female)		Age (Years)
Study	Language	Placebo	UPA	Placebo	UPA	Placebo	UPA
Navarro-Compán, 2023 [18]	English	209	211	158/51	153/58	42.2 ± 11.8	42.6 ± 12.4
Kiltz, 2023 [19]	English	157	156	63/94	67/89	42.5 ± 12.4	41.6 ± 12.0
Deodhar, 2022a [20]	English	157	156	63/94	67/89	42.5 ± 12.4	41.6 ± 12.0
van der Heijde, 2022 [16]	English	209	211	158/51	153/58	42.2 ± 11.8	42.6 ± 12.4
Deodhar, 2022b [21]	English	94	93	69/25	63/30	43.7 ± 12.1	47.0 ± 11.8
van der Heijde, 2019 [22]	English	94	93	69/25	63/30	43.7 ± 12.1	47.0 ± 11.8

ISSN: 2520-1026